1
|
Havlíček R, Šaňák D, Černík D, Neradová J, Leško N, Gdovinová Z, Köcher M, Cihlář F, Malik J, Fedorko J, Pedowski P, Zapletalová J. Predictors of Good Clinical Outcome After Endovascular Treatment for Acute Ischemic Stroke due to Tandem Lesion in Anterior Circulation: Results from the ASCENT Study. Cardiovasc Intervent Radiol 2024; 47:218-224. [PMID: 38216741 PMCID: PMC10844141 DOI: 10.1007/s00270-023-03649-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Accepted: 12/11/2023] [Indexed: 01/14/2024]
Abstract
PURPOSE Endovascular treatment (EVT) of tandem lesion (TL) in anterior circulation (AC) acute ischemic stroke (AIS) represents still a clinical challenge. We aimed to evaluate selected factors related to EVT and assess other possible predictors of good clinical outcome besides the generally known ones. METHODS AIS patients with TL in AC treated with EVT were enrolled in the multicenter retrospective ASCENT study. A good three-month clinical outcome was scored as 0-2 points in modified Rankin Scale (mRS) and achieved recanalization using the TICI scale. Symptomatic intracerebral hemorrhage (SICH) was assessed using the SITS-MOST criteria. Logistic regression analysis was used for the assessment of possible predictors of mRS 0-2 with adjustment for potential confounders. RESULTS In total, 300 (68.7% males, mean age 67.3 ± 10.2 years) patients with median of admission NIHSS 17 were analyzed. Recanalization (TICI 2b-3) was achieved in 290 (96.7%) patients and 176 (58.7%) had mRS 0-2. Besides the age, admission NIHSS and SICH, admission glycemia (p = 0.005, OR: 0.884) the stent patency within the first 30 days after EVT (p = 0.0003, OR: 0.219), dual antiplatelet therapy (DAPT) started within 12 h after EVT (p < 0.0001, OR: 5.006) and statin therapy started within 24 h after stenting (p < 0.0001, OR: 5.558) were found as other predictors. CONCLUSION Admission glycemia, start of DAPT within 12 h and statin therapy within 24 h after EVT, and stent patency within the first 30 days after EVT were found as other predictors of good three-month clinical outcome in AIS patients treated with EVT for TL.
Collapse
Affiliation(s)
- Roman Havlíček
- Comprehensive Stroke Center, Department of Neurology, Palacký University Medical School and University Hospital Olomouc, Olomouc, Czech Republic
- Comprehensive Stroke Center, Department of Neurology, Central Military Hospital Prague, Prague, Czech Republic
| | - Daniel Šaňák
- Comprehensive Stroke Center, Department of Neurology, Palacký University Medical School and University Hospital Olomouc, Olomouc, Czech Republic.
| | - David Černík
- Comprehensive Stroke Center, Department of Neurology, Masaryk Hospital, KZ a.S., Ústí Nad Labem, Czech Republic
| | - Jarmila Neradová
- Comprehensive Stroke Center, Department of Neurology, Masaryk Hospital, KZ a.S., Ústí Nad Labem, Czech Republic
| | - Norbert Leško
- Department of Neurology, P.J. Šafarik University, Faculty of Medicine and University Hospital L. Pasteur Košice, Košice, Slovakia
| | - Zuzana Gdovinová
- Department of Neurology, P.J. Šafarik University, Faculty of Medicine and University Hospital L. Pasteur Košice, Košice, Slovakia
| | - Martin Köcher
- Department of Radiology, Palacký University Medical School and University Hospital Olomouc, Olomouc, Czech Republic
| | - Filip Cihlář
- Department of Radiology, J. E. Purkinje University, Masaryk Hospital, KZ a.S., Ústí Nad Labem, Czech Republic
| | - Jozef Malik
- Department of Radiology, Central Military Hospital Prague, Prague, Czech Republic
| | - Jakub Fedorko
- Department of Radiodiagnostics and Imagine Techniques, P.J. Šafarik University, Faculty of Medicine and University Hospital L. Pasteur Košice, Košice, Slovakia
| | - Piotr Pedowski
- Department of Radiodiagnostics and Imagine Techniques, P.J. Šafarik University, Faculty of Medicine and University Hospital L. Pasteur Košice, Košice, Slovakia
| | - Jana Zapletalová
- Department of Biophysics and Statistics, Palacký University Medical School Olomouc, Olomouc, Czech Republic
| |
Collapse
|
2
|
Yao M, Hao Y, Wang T, Xie M, Li H, Feng J, Feng L, Ma D. A review of stress-induced hyperglycaemia in the context of acute ischaemic stroke: Definition, underlying mechanisms, and the status of insulin therapy. Front Neurol 2023; 14:1149671. [PMID: 37025208 PMCID: PMC10070880 DOI: 10.3389/fneur.2023.1149671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2023] [Accepted: 02/21/2023] [Indexed: 04/08/2023] Open
Abstract
The transient elevation of blood glucose produced following acute ischaemic stroke (AIS) has been described as stress-induced hyperglycaemia (SIH). SIH is common even in patients with AIS who have no previous diagnosis of diabetes mellitus. Elevated blood glucose levels during admission and hospitalization are strongly associated with enlarged infarct size and adverse prognosis in AIS patients. However, insulin-intensive glucose control therapy defined by admission blood glucose for SIH has not achieved the desired results, and new treatment ideas are urgently required. First, we explore the various definitions of SIH in the context of AIS and their predictive value in adverse outcomes. Then, we briefly discuss the mechanisms by which SIH arises, describing the dual effects of elevated glucose levels on the central nervous system. Finally, although preclinical studies support lowering blood glucose levels using insulin, the clinical outcomes of intensive glucose control are not promising. We discuss the reasons for this phenomenon.
Collapse
Affiliation(s)
- Mengyue Yao
- Department of Neurology and Neuroscience Centre, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Yulei Hao
- Department of Neurology and Neuroscience Centre, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Tian Wang
- Department of Neurology and Neuroscience Centre, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Meizhen Xie
- Department of Neurology and Neuroscience Centre, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Hui Li
- Department of Neurology and Neuroscience Centre, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Jiachun Feng
- Department of Neurology and Neuroscience Centre, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Liangshu Feng
- Stroke Centre, Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin, China
- Liangshu Feng
| | - Di Ma
- Department of Neurology and Neuroscience Centre, The First Hospital of Jilin University, Changchun, Jilin, China
- *Correspondence: Di Ma
| |
Collapse
|
3
|
Gerbaud E, Bouchard de La Poterie A, Baudinet T, Montaudon M, Beauvieux MC, Lemaître AI, Cetran L, Seguy B, Picard F, Vélayoudom FL, Ouattara A, Kabore R, Coste P, Domingues-Dos-Santos P, Catargi B. Glycaemic Variability and Hyperglycaemia as Prognostic Markers of Major Cardiovascular Events in Diabetic Patients Hospitalised in Cardiology Intensive Care Unit for Acute Heart Failure. J Clin Med 2022; 11:jcm11061549. [PMID: 35329874 PMCID: PMC8951492 DOI: 10.3390/jcm11061549] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Revised: 03/05/2022] [Accepted: 03/09/2022] [Indexed: 12/12/2022] Open
Abstract
(1) Background: Hyperglycaemia and hypoglycaemia are both emerging risk factors for cardiovascular disease. Nevertheless, the potential effect of glycaemic variability (GV) on mid-term major cardiovascular events (MACE) in diabetic patients presenting with acute heart failure (AHF) remains unclear. This study investigates the prognostic value of GV in diabetic patients presenting with acute heart failure (AHF). (2) Methods: this was an observational study including consecutive patients with diabetes and AHF between January 2015 and November 2016. GV was calculated using standard deviation of glycaemia values during initial hospitalisation in the intensive cardiac care unit. MACE, including recurrent AHF, new-onset myocardial infarction, ischaemic stroke and cardiac death, were recorded. The predictive effects of GV on patient outcomes were analysed with respect to baseline characteristics and cardiac status. (3) Results: In total, 392 patients with diabetes and AHF were enrolled. During follow-up (median (interquartile range) 29 (6−51) months), MACE occurred in 227 patients (57.9%). In total, 92 patients died of cardiac causes (23.5%), 107 were hospitalised for heart failure (27.3%), 19 had new-onset myocardial infarction (4.8%) and 9 (2.3%) had an ischaemic stroke. Multivariable logistic regression analysis showed that GV > 50 mg/dL (2.70 mmol/L), age > 75 years, reduced left ventricular ejection fraction (LVEF < 30%) and female gender were independent predictors of MACE: hazard ratios (HR) of 3.16 (2.25−4.43; p < 0.001), 1.54 (1.14−2.08; p = 0.005), 1.47 (1.06−2.07; p = 0.02) and 1.43 (1.05−1.94; p = 0.03), respectively. (4) Conclusions: among other well-known factors of HF, a GV cut-off value of >50 mg/dL was the strongest independent predictive factor for mid-term MACE in patients with diabetes and AHF.
Collapse
Affiliation(s)
- Edouard Gerbaud
- Cardiology Intensive Care Unit and Interventional Cardiology, Hôpital Cardiologique du Haut-Lévêque, 33604 Pessac, France; (A.B.d.L.P.); (T.B.); (L.C.); (B.S.); (P.C.)
- Bordeaux Cardio-Thoracic Research Centre, U1045, Bordeaux University, 33076 Bordeaux, France; (M.M.); (P.D.-D.-S.)
- Correspondence: ; Tel.: +33-524-549-188; Fax: +33-557-636-316
| | - Ambroise Bouchard de La Poterie
- Cardiology Intensive Care Unit and Interventional Cardiology, Hôpital Cardiologique du Haut-Lévêque, 33604 Pessac, France; (A.B.d.L.P.); (T.B.); (L.C.); (B.S.); (P.C.)
| | - Thomas Baudinet
- Cardiology Intensive Care Unit and Interventional Cardiology, Hôpital Cardiologique du Haut-Lévêque, 33604 Pessac, France; (A.B.d.L.P.); (T.B.); (L.C.); (B.S.); (P.C.)
| | - Michel Montaudon
- Bordeaux Cardio-Thoracic Research Centre, U1045, Bordeaux University, 33076 Bordeaux, France; (M.M.); (P.D.-D.-S.)
| | - Marie-Christine Beauvieux
- Biochemistry Laboratory, Hôpital Cardiologique du Haut-Lévêque, Bordeaux University, 33600 Pessac, France;
- Centre de Résonance Magnétique des Systèmes Biologiques, UMR 5536, CNRS, Bordeaux University, 33076 Bordeaux, France
| | - Anne-Iris Lemaître
- Advanced Heart Failure Unit, Department of Cardiovascular Medicine, Hôpital Cardiologique du Haut-Lévêque, Bordeaux University, 33604 Pessac, France; (A.-I.L.); (F.P.)
| | - Laura Cetran
- Cardiology Intensive Care Unit and Interventional Cardiology, Hôpital Cardiologique du Haut-Lévêque, 33604 Pessac, France; (A.B.d.L.P.); (T.B.); (L.C.); (B.S.); (P.C.)
| | - Benjamin Seguy
- Cardiology Intensive Care Unit and Interventional Cardiology, Hôpital Cardiologique du Haut-Lévêque, 33604 Pessac, France; (A.B.d.L.P.); (T.B.); (L.C.); (B.S.); (P.C.)
| | - François Picard
- Advanced Heart Failure Unit, Department of Cardiovascular Medicine, Hôpital Cardiologique du Haut-Lévêque, Bordeaux University, 33604 Pessac, France; (A.-I.L.); (F.P.)
| | - Fritz-Line Vélayoudom
- Department of Diabetology-Endocrinology, University Hospital of Guadeloupe, 97159 Pointe-à-Pitre, France;
- Inserm UMR 1283, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, 59000 Lille, France
| | - Alexandre Ouattara
- Department of Anesthesia and Critical Care, Magellan Medico-Surgical Centre, Bordeaux University, 33600 Pessac, France;
- Biology of Cardiovascular Diseases Centre, U1034, Bordeaux University, 33600 Pessac, France
| | - Rémi Kabore
- Institut de Santé Publique, d’Épidémiologie et de Développement (ISPED), Bordeaux Population Health Research, U1219, Bordeaux University, 33000 Bordeaux, France;
| | - Pierre Coste
- Cardiology Intensive Care Unit and Interventional Cardiology, Hôpital Cardiologique du Haut-Lévêque, 33604 Pessac, France; (A.B.d.L.P.); (T.B.); (L.C.); (B.S.); (P.C.)
- Bordeaux Cardio-Thoracic Research Centre, U1045, Bordeaux University, 33076 Bordeaux, France; (M.M.); (P.D.-D.-S.)
| | - Pierre Domingues-Dos-Santos
- Bordeaux Cardio-Thoracic Research Centre, U1045, Bordeaux University, 33076 Bordeaux, France; (M.M.); (P.D.-D.-S.)
- Advanced Heart Failure Unit, Department of Cardiovascular Medicine, Hôpital Cardiologique du Haut-Lévêque, Bordeaux University, 33604 Pessac, France; (A.-I.L.); (F.P.)
- Institut de Rythmologie et Modélisation Cardiaque (IHU Liryc), Fondation Bordeaux Université, 33600 Pessac, France
| | - Bogdan Catargi
- Endocrinology-Metabolic Diseases, Hôpital Saint-André, Bordeaux University, 33000 Bordeaux, France;
| |
Collapse
|